Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15447209 | 1.00 | AKT1 (0.35) | AKT1UGT2B7ADRB2BTKROCK1 | |
| SCHEMBL9905543 | 0.86 | UGT2B7 (0.47) | AKT1UGT2B7BTK | |
| SCHEMBL9905545 | 0.86 | UGT2B7 (0.47) | AKT1UGT2B7BTK | |
| SCHEMBL19479451 | 0.81 | AKT1 (0.30) | AKT1 | |
| SCHEMBL18562292 | 0.76 | AKR1C3 (0.32) | — | |
| SCHEMBL15448418 | 0.76 | ADRB2 (0.42) | AKT1UGT2B7ADRB2ROCK1 | |
| SCHEMBL16837784 | 0.74 | RIOK2 (0.33) | — | |
| SCHEMBL18828019 | 0.74 | — | — | |
| SCHEMBL14652449 | 0.71 | CYP1A2 (0.43) | AKT1 | |
| SCHEMBL2338713 | 0.70 | CYP1A2 (0.48) | AKT1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512175-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512175-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150344521-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344521-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344521-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | AKT1 3910/4885UGT2B7 74/4885ADRB2 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.